ArticleBriefings in bioinformatics2026
ZeCardioAI: combining zebrafish, AI, and xAI for an in-depth cardiac phenotyping platform.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
Artificial intelligence (AI) integrated with high-throughput assays offers a powerful route to accelerate discovery in relevant biological models. Functional cardiac imaging is a prime application, where deep learning (DL) and explainable AI (xAI) can overcome limitations of traditional phenotyping methods, such as manual analysis, subjective interpretation, and low scalability. In cardiovascular research, the zebrafish model is highly valuable due to its translational relevance and accessibility for high-throughput applications. Here, we present ZeCardioAI, a computational platform combining zebrafish experimental advantages with DL and xAI methodologies. The platform automatically extracts comprehensive cardiac phenotypes from live imaging, achieving high precision while maintaining interpretability, critical for mechanistic insight and translational validation. ZeCardioAI, when applied to zebrafish models of dilated and hypertrophic cardiomyopathy (CM), detected subtle yet clinically relevant phenotypic differences. Machine learning classifiers achieved robust separation of disease from healthy phenotypes, and xAI revealed discriminative features aligning with established clinical markers. Our developments should prove valuable in addressing the unmet medical need in CMs to find new, specific treatments. The platform's modular architecture supports future adaptation to diverse disease contexts beyond CMs, enabling large-scale, fully automated phenotyping at a throughput unattainable by manual approaches. ZeCardioAI establishes a new standard for AI-powered biological research, offering transformative potential for accelerating drug discovery, advancing precision medicine approaches, and deepening fundamental understanding of complex biological systems across multiple therapeutic areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.